Skip to main content
Journal of Obesity & Metabolic Syndrome logoLink to Journal of Obesity & Metabolic Syndrome
. 2026 Oct 19;35(4):460–477. doi: 10.7570/jomes25048

Relationship between Vitamin D Status and the Risk of Obesity without Diagnosed Metabolic Syndrome: A Meta-Analysis of Observational Studies

Yueqing Liang 1,#, Xin Luo 1,#, Xueyi Jiang 1,#, Tianyi Teng 1, Kemin Qi 1, Ping Li 1,*
PMCID: PMC13744985  PMID: 42893821

Abstract

Background

The association between daily vitamin D (VD) intake and the risk of healthy obesity remains controversial.

Methods

PubMed, Embase, Web of Science, Wanfang Database, China Science and Technology Periodical Database, and the Cochrane Database of Systematic Reviews were systematically searched for published observational studies up to January 2025. Ultimately, 74 studies were included, and pooled estimates were obtained using RevMan version 5.3. Subgroup analyses were conducted by age, VD detection method and assessment criteria, and obesity grade.

Results

Among 5,283 articles identified, 74 studies with 110,838 individuals met the inclusion criteria. Serum/plasma 25-hydroxyvitamin D concentrations were negatively associated with the risk of healthy obesity (mean difference=–3.98; 95% confidence interval [CI], –4.70 to –3.27). Significant differences between the obesity and control groups were observed in all subgroups except those using liquid chromatography-tandem mass spectrometry/mass spectrometry (LC-MS/MS) detection. Moreover, the prevalence of VD deficiency was higher in participants with obesity than in controls (odds ratio [OR], 2.02; 95% CI, 1.73 to 2.36). This difference was significant in all subgroups except those in which VD deficiency was defined as a concentration below 10 or 12 ng/mL. Furthermore, VD insufficiency was positively associated with the risk of obesity (OR, 1.17; 95% CI, 1.04 to 1.32). However, significant differences were observed only in specific subgroups: adolescents, participants with mild obesity, and those assessed using enzyme-linked immunosorbent assay or LC-MS/MS detection methods.

Conclusion

These findings indicated that VD status was inversely associated with the risk of healthy obesity, irrespective of age and obesity grade. Inconsistencies may be influenced by VD detection methods and assessment criteria.

Keywords: Vitamin D, Deficiency, Obesity, Meta-analysis, Observational study

INTRODUCTION

The prevalence of obesity has increased dramatically worldwide, affecting more than 20%–30% of people and posing a serious public health problem.1 Obesity is regarded as the most common form of malnutrition in numerous countries, affecting more than 1 billion children, adolescents, and adults. The development of obesity involves both adipose tissue expansion and angiogenesis. However, obesity does not always entail metabolic abnormalities or an increased risk of metabolic syndrome (MetS), as illustrated by the metabolically healthy obesity (MHO) phenotype. The prognosis of MHO remains debated, mainly because it may gradually progress to metabolically unhealthy obesity (MUO), worsening the progression of MetS.2 Thus, effective classification of obesity based on metabolic health status is needed to identify high-risk individuals and optimize future prevention and treatment strategies.

Unhealthy dietary patterns and lifestyle behaviors are strongly associated with an increased risk of obesity, including insufficient intake of nutrients such as vitamin D (VD).3 VD plays an important hormonal role in regulating gene expression, parathyroid hormone, calcium, and adipocytokine secretion, which may affect adipose tissue differentiation, proliferation, and adhesion.2,3 However, evidence that insufficient VD intake predisposes individuals to obesity or aggravates its progression is inconsistent. This relationship has not been fully explored. VD receptors have been identified in adipose tissue, and low VD concentrations cannot yet be ruled out as a cause of obesity.1-3 Animal and in vitro studies have also demonstrated positive associations between obesity and the prevalence of VD deficiency.2,3 However, epidemiological and clinical studies have yielded conflicting results because of important limitations and confounding factors. Haghighat et al.3 reported that serum 25-hydroxyvitamin D (25(OH)D) levels were negatively correlated with obesity and related parameters, including body mass index (BMI), adiposity, and waist circumference.2-7 In contrast, Li et al.,4 Poomthavorn et al.,5 Aypak et al.,6 and Gariballa et al.7 reported no meaningful relationships between obesity-related indicators and low serum VD concentrations. Moreover, some studies found that VD supplementation did not reduce body weight in individuals with obesity.6 Other studies of the interactions between VD and adipose tissue reported that VD supplementation was associated with a reduction in MetS during the progression of obesity through regulation of adipose tissue inflammation and hepatic steatosis.7-9 Therefore, whether VD supplementation benefits weight control and reduction by improving metabolic disorders remains uncertain.

These uncertain associations may have several explanations. First, obesity develops over a long period, whereas many randomized controlled trials did not use a standardized duration of VD intervention. Such interventions may increase serum 25(OH)D levels without corresponding benefits because the intervention period is too short. Second, associations between obesity risk and low 25(OH)D levels may be explained by limited outdoor activity and unhealthy diets, both of which contribute to an increased risk of obesity and related metabolic complications.3 Third, circulating 25(OH)D can be activated through two hydroxylation reactions involving the liver and kidney. Dysfunction of these organs in individuals with obesity may conversely result in abnormal VD status and contribute to inconsistent findings. Finally, differences in age, VD intake, detection methods, and deficiency criteria may confound the results across study populations.4-6 Thus, evidence on the relationship between VD deficiency and obesity without diagnosed MetS should be synthesized to inform future studies and public policies. The objective of the present study was therefore to evaluate the associations between VD status and the risk of obesity in participants without diagnosed MetS, using subgroup analyses by age, VD detection method, criteria for VD deficiency and insufficiency, and obesity grade.

METHODS

The protocol of this meta-analysis evaluating the relationships between VD status and the risk of obesity without diagnosed MetS was registered in the PROSPERO database (registration number: CRD42025636601). This systematic review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.7,8

Search strategy and data sources

A comprehensive search strategy was used to search PubMed, Embase, Web of Science, Wanfang Database, China Science and Technology Periodical Database, and the Cochrane Database of Systematic Reviews for published observational studies up to January 2025 evaluating the associations between VD status and the risk of obesity without diagnosed MetS (Table 1). Systematic reviews and meta-analyses were also searched. The searches used the following Medical Subject Headings (MeSH) and non-MeSH terms: ‘25(OH)D,’ ‘1,25-dihydroxyvitamin D,’ and ‘1,25(OH)2D,’ together with ‘obesity,’ ‘obesity phenotype,’ ‘body mass index,’ ‘BMI,’ ‘metabolic syndrome,’ ‘metabolic health,’ ‘metabolically benign,’ ‘metabolically healthy obesity,’ ‘MetS,’ or ‘MHO.’

Table 1.

Basic characteristics of the included observational studies

Author (year) Country Sample (n)* Population Detection method Outcome Quality§
Male/Female* (n) Age* (yr) BMI criteria 25(OH)D (ng/mL)* Deficiency (%) [criteria, ng/mL]†,‡ Insufficiency (%) [criteria, ng/mL]†,‡
Çelik et al. (2021)10 Türkiye 90 (83) 32/58 (33/50) 14.4 ± 1.8 (14.6 ± 1.6) BMI ≥ 95th ECLIA 12.1 ± 5.8 (16.4 ± 9.3) 65 (72.2), 48 (57.8) [< 15] 16 (17.8), 13 (15.7) [15 ≤ I < 20] 8
Barja-Fernández et al. (2018)11 Spain 176 (125) - 10.2 ± 3.2 (10.9 ± 3.4) BMI ≥ 95th CLIA 26.3 ± 14.9 (30.6 ± 17.9) 79 (44.9), 43 (34.4) [< 20] 46 (26.1), 34 (27.2) [20 ≤ I < 30] 8
Gün et al. (2020)12 Türkiye 92 (58) 42/50 (27/31) 9.5 ± 3.1 (10.3 ± 3.3) BMI ≥ 95th ELISA 12.7 ± 8.3 (15.2 ± 6.1) 75 (81.5), 28 (48.3) [< 15] 14 (15.2), 24 (41.4) [15 ≤ I < 20] 8
Bellone et al. (2014)13 Italy 444 (113) 219/225 (68/45) 10.6 ± 0.2 (13.5 ± 0.2) BMI ≥ 95th CLIA 21.8 ± 0.6 (27.3 ± 1.2) 197 (44.4), 36 (31.8) [< 20] 163 (36.7), 45 (39.9) [20 ≤ I < 30] 8
Colak et al. (2020)14 Türkiye 40 (30) 22/18 (12/18) 11.3 ± 3.9 (10.3 ± 5.2) BMI ≥ 95th CLIA 16.4 ± 7.7 (19.6 ± 16.3) 30 (75.0), 15 (50.0) [< 20] - 6
Flores et al. (2017)15 Mexico 827 (473) - 1–11 (1–11) BMIZ ≥ 2 CLIA - 394 (47.7), 140 (29.5) [< 20] - 6
Huang et al. (2015)16 China 203 (445) - 10.3 ± 1.4 (10.5 ± 1.2) BMI ≥ 95th ELISA 19.6 ± 7.1 (23.5 ± 7.3) 20 (9.9), 18 (4.1) [< 12] 96 (47.2), 138 (31.1) [12 ≤ I < 20] 8
Saarnio et al. (2018)17 Finland 104 (242) 36/68 (56/186) 42.3 ± 2.8 (42.0 ± 2.9) BMI ≥ 95th ELISA 19.9 ± 7.3 (22.6 ± 7.4) - - 7
Moschonis et al. (2018)18 Greece 261 (1,313) - 9–13 (9–13) BMI ≥ 95th ELISA - 17 (6.5), 69 (5.3) [< 12] 158 (60.5), 669 (51.0) [12 ≤ I < 20] 7
Wakayo et al. (2016)19 Ethiopia 18 (156) 2/16 (73/83) 11–18 (11–18) BMI ≥ 95th LC-MS/MS - 14 (77.8), 59 (37.8) [< 20] - 7
Chen et al. (2021)20 China 37 (1,317) - 2–6 (2–6) BMI ≥ 95th LC-MS/MS 25.5 ± 7.3 (28.2 ± 7.2) 9 (24.3), 138 (10.5) [< 20] 17 (45.9), 703 (53.4) [20 ≤ I < 30] 8
Zhao et al. (2023)21 China 264 (5,020) - 0–5 (0–5) BMI ≥ 95th ELISA 23.9 ± 5.4 (25.6 ± 5.8) 95 (36.0), 1,495 (29.8) [< 20] - 7
Gilbert-Diamond et al. (2010)22 Colombia 200 (200) - 5–12 (5–12) BMI ≥ 30.0 ELISA 26.9 ± 5.6 (29.8 ± 8.8) - - 6
Guo et al. (2021)23 China 69 (345) 51/18 (164/181) 0–3 (0–3) BMI ≥ 95th ELISA 13.0 ± 4.9 (14.6 ± 6.3) 26 (37.7), 55 (15.9) [< 20] 25 (36.2), 168 (48.7) [20 ≤ I < 30] 8
Jari et al. (2015)24 Iran 104 (700) 60/44 (353/347) 14.7 ± 2.6 (14.7 ± 2.6) BMI ≥ 95th CLIA - 43 (41.3), 279 (39.9) [< 10] 43 (41.3), 260 (37.1) [10 ≤ I < 30] 7
Khor et al. (2011)25 Malaysia 66 (233) 45/21 (88/145) 7–12 (7–12) BMI ≥ 95th ELISA - 54 (81.8), 163 (70.0) [< 20] - 6
Krivošíková et al. (2022)26 Slovakia 120 (51) 57/63 (25/26) 13.0 ± 2.9 (12.6 ± 3.1) BMI ≥ 95th ELISA 27.8 ± 8.6 (34.2 ± 9.3) 19 (15.8), 1 (2.0) [< 20] 54 (45.0), 16 (31.4) [20 ≤ I < 30] 8
Zou et al. (2022)27 China 297 (1,980) - 6–17 (6–17) BMI ≥ 95th ELISA 2.9 ± 0.7 (2.8 ± 0.7) 1 (0.3), 37 (2.0) [< 20] 86 (29.0), 656 (33.1) [20 ≤ I < 30] 8
Usman et al. (2021)28 Britain 53 (59) 24/29 (27/32) 14.6 ± 2.1 (13.6 ± 2.4) BMI ≥ 99th ELISA 6.3 ± 5.2 (7.6 ± 3.6) - - 6
Al-Sultan et al. (2011)29 Saudi Arabia 76 (84) 40/36 (42/42) 22.8 ± 1.9 (22.5 ± 1.2) BMI ≥ 30.0 HPLC 13.2 ± 4.8 (16.2 ± 7.7) 29 (38.2), 19 (22.7) [< 15] 12 (15.8), 16 (19.0) [15 ≤ I < 20] 7
Olson et al. (2012)30 USA 411 (87) 234/177 (59/28) 11.7 ± 2.6 (11.2 ± 3.0) BMI ≥ 95th CLIA 19.6 ± 7.1 (27.0 ± 10.7) 207 (50.3), 19 (21.8) [< 20] 166 (40.5), 40 (46.0) [20 ≤ I < 30] 8
Ghergherechi et al. (2012)31 Iran 52 (57) - 8.9 ± 7.2 (7.2 ± 2.1) BMI ≥ 95th CLIA 32.7 ± 29.6 (44.2 ± 11.2) 40 (76.9), 19 (33.3) [< 20] - 6
Dyląg et al. (2014)32 Poland 50 (50) - 3.2 ± 1.1 (3.0 ± 1.2) BMI ≥ 95th CLIA 23.6 ± 10.8 (26.6 ± 9.8) 21 (42.0), 11 (22.0) [< 20] 19 (38.0), 24 (48.0) [20 ≤ I < 30] 8
Senaprom et al. (2016)33 Thailand 48 (429) - 3–13 (3–13) BMIZ ≥ 2 CLIA - 24 (50.0), 128 (29.8) [< 20] - 6
Orces (2018)34 Ecuador 433 (947) - 70.0 ± 7.3 (72.5 ± 8.4) BMI ≥ 30 LC-MS/MS 25.1 ± 10.9 (28.3 ± 8.4) 253 (58.5), 453 (47.8) [< 20] - 7
Aka et al. (2021)35 Türkiye 35 (48) 16/19 (25/23) 10.5 ± 3.3 (9.8 ± 3.2) BMI ≥ 95th HPLC 15.5 ± 10.7 (27.4 ± 14.7) 18 (51.4), 11 (22.9) [< 12] - 7
Al-Musharaf et al. (2012)36 Saudi Arabia 124 (207) 54/70 (99/108) 13.0 ± 3.0 (12.0 ± 2.1) BMI ≥ 95th ELISA 8.6 ± 4.6 (9.2 ± 6.9) - - 6
Durá-Travé et al. (2021)37 Spain 282 (348) 155/127 (172/176) 11.2 ± 4.0 (11.0 ± 3.9) BMIZ ≥ 3 CLIA - 127 (45.0), 38 (10.9) [< 20] 118 (41.8), 164 (47.1) [20 ≤ I < 30] 7
Durá-Travé et al. (2019)38 Spain 119 (300) 59/60 (132/168) 11.5 ± 2.4 (11.2 ± 3.1) BMIZ ≥ 2 CLIA 21.9 ± 8.1 (27.9 ± 7.5) 37 (31.1), 42 (14.0) [< 20] 48 (40.3), 132 (44.0) [20 ≤ I < 30] 8
Jaksic et al. (2019)39 Montenegro 35 (85) - 10.8 ± 1.7 (10.8 ± 1.6) BMI ≥ 30 CLIA 27.8 ± 4.1 (30.9 ± 3.9) - - 6
Shulhai et al. (2019)40 Ukraine 74 (63) - 15.4 ± 2.3 (15.3 ± 2.2) BMI ≥ 99th ELISA 13.9 ± 2.7 (19.8 ± 4.3) - - 6
Elizondo-Montemayor et al. (2010)41 Mexico 99 (99) 50/49 (50/49) 9.0 ± 2.0 (8.9 ± 2.0) BMI ≥ 95th CLIA 23.1 ± 5.4 (26.4 ± 6.1) 27 (27.3), 13 (13.1) [< 20] 64 (64.6), 59 (59.6) [20 ≤ I < 30] 8
Peterson et al. (2014)42 Türkiye 118 (68) 59/59 (33/35) 12.0 ± 2.2 (12.6 ± 1.7) BMI ≥ 95th ECLIA 14.4 ± 8.1 (18.6 ± 9.5) - - 6
Simunovic et al. (2021)43 Croatia 92 (39) 52/40 (18/21) 14.0 ± 2.3 (14.4 ± 2.2) BMIZ > 2 ECLIA 20.8 ± 7.2 (25.6 ± 10.3) 8 (8.6), 1 (2.6) [< 12] 42 (45.7), 11 (28.2) [12 ≤ I < 20] 7
Reinehr et al. (2007)44 Germany 133 (23) 68/65 (12/11) 12.1 ± 2.4 (11.9 ± 1.9) BMIZ ≥ 2 ECLIA 16.7 ± 3.1 (24.8 ± 5.2) - - 6
Rojas et al. (2020)45 Colombia 138 (356) 72/66 (167/189) 16.0 ± 1.1 (16.0 ± 1.8) BMIZ ≥ 2 CMIA 25.9 ± 4.1 (27.6 ± 5.3) 23 (16.7), 59 (16.6) [< 20] 79 (57.2), 161 (45.2) [20 ≤ I < 30] 8
Li et al. (2022)4 China 84 (1,442) - 0–18 (0–18) BMI ≥ 95th ELISA 45.9 ± 12.8 (46.3 ± 12.6) 2 (2.4), 12 (0.8) [< 20] 16 (19.0), 107 (7.4) [20 ≤ I < 30] 8
Zhang et al. (2014)46 China 164 (1,112) - 7–11 (7–11) BMI ≥ 95th HPLC - 113 (68.9), 586 (52.7) [< 20] - 7
Liu et al. (2022)47 China 273 (226) 184/89 (142/84) 2–18 (2–18) BMIZ > 2 ECLIA 19.6 ± 8.8 (24.8 ± 9.6) 54 (19.8), 16 (7.1) [< 12] 101 (37.0), 67 (29.7) [12 ≤ I < 20] 8
Xie et al. (2020)48 China 225 (227) - 3–18 (3–18) BMI ≥ 95th CMIA 21.5 ± 11.2 (28.4 ± 12.5) 100 (44.4), 56 (24.7) [< 10] 101 (44.9), 89 (39.2) [10 ≤ I < 30] 8
Wang et al. (2016)49 China 103 (175) 63/40 (77/98) 12.1 ± 1.8 (12.2 ± 1.9) BMI ≥ 95th ECLIA 20.7 ± 6.0 (22.6 ± 8.2) 4 (3.9), 6 (3.4) [< 12] 39 (37.9), 76 (43.4) [12 ≤ I < 20] 8
Vierucci et al. (2013)50 Italy 114 (288) - 2.0–21.0 (2.0–21.0) BMI ≥ 30 CMIA 19.5 ± 15.2 (21.2 ± 15.6) 59 (51.8), 128 (44.4) [< 20] 45 (39.5), 89 (30.9) [20 ≤ I < 30] 8
Makariou et al. (2020)51 Greece 69 (34) 31/38 (15/19) 12.0 ± 2.0 (12.6 ± 2.0) BMI ≥ 95th ELISA 12.0 ± 9.0 (34.0 ± 21.3) - - 6
Poomthavorn et al. (2012)5 Thailand 150 (29) 76/74 (4/25) 11.2 ± 2.6 (8.7 ± 1.5) BMIZ ≥ 2 HPLC 28.2 ± 6.6 (27.6 ± 5.5) 17 (11.3), 3 (10.3) [< 20] - 8
Plesner et al. (2018)52 Denmark 1,484 (2,143) 676/808 (856/1,287) 11.8 ± 2.8 (12.1 ± 3.4) BMIZ ≥ 2 ECLIA 19.2 ± 8.7 (23.7 ± 9.2) 245 (16.5), 103 (4.8) [< 12] 637 (42.9), 630 (29.4) [12 ≤ I < 20] 8
Hu et al. (2022)53 China 5,868 (44,840) - 6–18 (6–18) BMI ≥ 95th LC-MS/MS 17.5 ± 4.4 (17.6 ± 4.5) 1,215 (20.7), 9,641 (21.5) [< 12] 2,746 (46.8), 19,909 (44.4) [12 ≤ I < 20] 7
Nikooyeh et al. (2020)54 Iran 25 (33) - 9.3 ± 3.3 (9.8 ± 3.1) BMIZ ≥ 2 CLIA 8.8 ± 3.9 (12.4 ± 6.6) - - 6
Sacheck et al. (2011)55 USA 65 (139) - 9–14 (9–14) BMI ≥ 95th CLIA - 52 (80.0), 97 (69.8) [< 20] - 6
Liu et al. (2016)56 China 304 (139) 196/108 (87/52) 0–18 (0–18) BMI ≥ 95th CMIA 18.3 ± 10.8 (36.1 ± 6.0) - - 6
Kitsos et al. (2018)57 Greece 104 (50) 55/49 (26/24) 62.5 ± 12.1 (60.8 ± 13.0) BMI ≥ 30 ELISA 19.9 ± 6.4 (24.9 ± 6.3) - - 6
Al-Sadat et al. (2016)58 Malaysia 116 (738) 56/60 (282/456) 12.9 ± 0.3 (12.8 ± 0.5) BMI ≥ 95th CMIA - 102 (88.0), 560 (75.8) [< 15] 7 (6.0), 120 (16.3) [15 ≤ I < 20] 7
Aypak et al. (2014)6 Türkiye 44 (90) 23/21 (47/43) 10.0 ± 4.1 (11.0 ± 6.5) BMI ≥ 95th CMIA 10.2 ± 5.0 (9.5 ± 5.5) - - 6
Panfili et al. (2023)59 Italy 93 (59) - 11.2 ± 3.4 (11.6 ± 4.6) BMIZ ≥ 2 CMIA - 4 (4.3), 1 (1.7) [< 12] 36 (38.7), 18 (30.5) [12 ≤ I < 20] 8
Gariballa et al. (2022)7 United Arab Emirates 106 (65) 80/26 (52/13) 45.0 ± 11.0 (34.0 ± 12.0) BMI ≥ 30 LC-MS/MS 22.9 ± 11.0 (23.7 ± 11.0) - - 7
Clark et al. (2021)60 Mexico 33 (187) - 2–17 (2–17) BMIZ ≥ 2 LC-MS/MS - 24 (72.7), 48 (25.8) [< 20] - 6
Durá-Travé et al. (2017)61 Spain 122 (355) 46/76 (163/192) 10.6 ± 2.8 (9.7 ± 3.3) BMIZ ≥ 2 CMIA 26.2 ± 7.0 (28.1 ± 7.7) 32 (26.2), 43 (12.1) [< 20] 57 (46.7), 163 (45.9) [20 ≤ I < 30] 8
Turer et al. (2013)62 USA 2,478 (7,728) - 6–18 (6–18) BMI ≥ 99th CMIA 930 (37.5), 1,623 (21.0) [< 20] 6
Hyppönen et al. (2006)63 Britain 1,693 (2,522) - 45 (45) BMI ≥ 30 CMIA - 902 (53.3), 933 (37.0) [< 20] 530 (31.3), 857 (34.0) [20 ≤ I < 30] 7
Lee et al. (2013)64 Korea 241 (1,408) - 9 (9) BMI ≥ 95th CMIA 17.3 ± 4.6 (19.1 ± 5.0) - - 6
Absoud et al. (2011)65 Britain 242 (860) - 4–18 (4–18) BMI ≥ 30 CMIA 25.2 ± 7.2 (23.3 ± 7.0) 98 (40.5), 289 (33.9) [< 10] - 7
Nesby-O'Dell et al. (2002)66 USA 471 (619) 0/471 (0/619) 15–49 (15–49) BMI ≥ 30 ELISA 21.3 ± 1.5 (27.2 ± 1.5) - - 6
Holvik et al. (2005)67 Norway 157 (400) - 31–60 (31–60) BMI ≥ 30 CMIA 10.1 ± 3.1 (12.6 ± 2.8) 68 (43.3), 126 (31.5) [< 20] - 7
Rockell et al. (2005)68 New Zealand 288 (875) - 5–14 (5–14) BMI ≥ 30 ELISA 17.6 ± 2.3 (20.0 ± 2.1) 6 (2.1), 26 (3.0) [< 7] 121 (42.0), 236 (27.0) [7 ≤ I < 15] 8
Bischof et al. (2006)69 Austria 286 (205) - 48.3 ± 16.0 (48.3 ± 16.0) BMI ≥ 30 CLIA - 43 (15.0), 18 (8.8) [< 10] 206 (72.0), 143 (69.7) [10 ≤ I < 30] 7
Çizmecioğlu et al. (2008)70 Türkiye 102 (54) - 11–19 (11–19) BMI ≥ 95th CMIA - 13 (12.7), 4 (7.4) [< 10] 51 (50.0), 34 (63.0) [10 ≤ I < 20] 6
Tseng et al. (2009)71 USA 39 (15) 39/0 (15/0) 49.6 ± 8.0 (49.6 ± 8.0) BMI ≥ 30 CMIA 12.4 ± 1.5 (15.0 ± 1.1) 28 (71.8), 8 (53.3) [< 15] - 6
Hyppönen et al. (2010)72 Britain 1,440 (2,361) - 45.0 (45.0) BMI ≥ 30 CMIA 18.7 ± 1.1 (22.1 ± 1.1) 139 (9.7), 178 (7.5) [< 10] 1,294 (89.8), 2,131 (90.3) [10 ≤ I < 30] 8
González et al. (2015)73 USA 348 (165) 53.7 ± 15.4 (53.7 ± 15.4) BMI ≥ 30 ELISA - 24 (6.9), 7 (4.2) [< 12] 120 (34.5), 49 (29.7) [12 ≤ I < 20] 7
Stokić et al. (2015)74 Serbia 50 (36) 16/34 (18/18) 38.2 ± 11.3 (33.6 ± 6.5) BMI ≥ 30 ELISA 10.9 ± 5.5 (25.8 ± 8.5) 44 (88.0), 11 (30.6) [< 20] - 7
Reyman et al. (2014)75 Netherlands 64 (32) - 12.6 ± 2.6 (11.1 ± 3.2) BMIZ ≥ 3 ELISA 14.7 ± 3.2 (26.0 ± 5.2) - - 8
Zhang et al. (2014)76 China 39 (31) - 4.7 ± 0.9 (4.7 ± 0.9) BMI ≥ 95th ELISA 35.6 ± 6.3 (44.6 ± 3.7) 7 (17.9), 1 (3.3) [< 20] - 7
Xiao et al. (2012)77 China 212 (235) 123/89 (119/116) 8.3 ± 0.6 (8.6 ± 0.5) BMI ≥ 95th ELISA - 62 (29.2), 30 (12.8) [< 15] 78 (36.8), 36 (15.3) [15 ≤ I < 20] 7
Alkerwi et al. (2015)78 Luxembourg 301 (566) - 18–69 (18–69) BMI ≥ 30 ECLIA - 62 (20.6), 77 (13.6) [< 20] 202 (67.1), 280 (49.5) [20 ≤ I < 30] 7
Miñambres et al. (2012)79 Spain 224 (117) - - BMI ≥ 30 CLIA - 132 (58.9), 49 (41.9) [< 20] - 6

Values are presented as mean ± standard error of mean, range, or number (%). Mild obesity: 95% ≤ BMI < 97% or 30 ≤ BMI < 35 or 2 ≤ BMIZ < 3; Moderate to severe obesity: BMI ≥ 97% or BMI ≥ 35 or BMIZ ≥ 3.

*Data for the obesity and control groups are shown outside and inside parentheses, respectively; †Numbers and prevalence rates are presented for the obesity and control groups, respectively; diagnostic criteria are enclosed in square brackets; ‡A 25(OH)D concentration of 1 ng/mL is equivalent to 2.5 nmol/L. According to the USA Endocrine Society Practice Guideline, 25(OH)D at a level of < 20 ng/mL was defined as deficiency, and 20–29 ng/mL was defined as insufficiency. According to the American Academy of Pediatrics, a 25(OH)D concentration of < 15 ng/mL was defined as deficiency, and 15−20 ng/mL was defined as insufficiency; §Methodological quality was assessed using the Newcastle-Ottawa Scale (NOS).

BMI, body mass index; 25(OH)D, 25-hydroxyvitamin D; ECLIA, electrochemiluminescence enzyme immunoassay; CLIA, chemiluminescence enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; BMIZ, BMI z-score; LC-MS/MS, liquid chromatography-tandem mass spectrometry/mass spectrometry; HPLC, high-performance liquid chromatography; CMIA, chemiluminescence microparticle immunoassay.

Eligibility criteria, inclusion, and exclusion

Eligibility was assessed using the Population, Intervention, Comparison, and Outcomes (PICO) framework and the following criteria: (1) Study types: Observational studies evaluating associations between VD status and the risk of obesity without diagnosed MetS were included, with no language restrictions. (2) Population: Studies of individuals with obesity without diagnosed MetS according to World Health Organization criteria, especially liver and kidney diseases, were included; no age or ethical specifications were applied. (3) Interventions: No interventions were evaluated in this meta-analysis. (4) Comparisons: Outcomes were compared between the obesity and control groups. (5) Outcomes: Studies comparing serum/plasma 25(OH)D concentrations and the prevalence of VD deficiency and insufficiency between the obesity and control groups were included. Differences in serum/plasma 25(OH)D concentrations were calculated as mean differences (MDs) with 95% confidence intervals (CIs). Odds ratios (ORs) with 95% CIs were used to compare the prevalence of VD deficiency and insufficiency between the two groups. Outcomes were then analyzed in subgroups defined by age, detection method, VD assessment criteria, and obesity grade. Studies that did not meet these criteria or were irrelevant to the research objectives were excluded, including systematic reviews and meta-analyses, animal experiments, case reports, and in vitro experiments. Duplicate articles were removed using EndNote software. Individuals with obesityrelated comorbidities that affect VD metabolism, such as hepatic, renal, and endocrine diseases, or who used relevant medications, including glucocorticoids and proton pump inhibitors, were also excluded. Studies with incomplete published data were excluded. The reference lists of retrieved articles were manually screened. The study selection process is shown in Fig. 1.

Figure 1.

Figure 1

Flow diagram of the study inclusion process.

Data extraction

Two trained reviewers (Yueqing Liang and Xin Luo) independently screened article titles, abstracts, and full texts against the predefined inclusion and exclusion criteria. When consensus could not be reached, a third reviewer (Ping Li) resolved disagreements about eligibility.

The following information was collected: the first author’s name, geographical location, definition of obesity, BMI and BMI z-score (BMIZ), number of obesity cases and obesity events, participant sex and age, criteria for VD deficiency and insufficiency, VD detection methods, and related metabolic risk factors, including fasting glucose, glucose, fasting insulin, insulin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, calcium, cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and homeostasis model assessment for insulin resistance.

Quality assessment and risk of bias

The methodological quality and risk of bias of the included studies were assessed using the Newcastle-Ottawa Scale (NOS) and the number of events per variable.7 Two authors (Yueqing Liang and Xin Luo), blinded to the study authors and institutions, independently rated eligible studies. Discrepancies were resolved at a consensus meeting. The NOS assessment included eight categories: adequate case definition, representativeness of cases, selection of controls, definition of controls, comparability of cases and controls, ascertainment of exposure, use of the same ascertainment method for cases and controls, and non-response rate. Each category was scored as 1 for ‘yes’ and 0 for ‘no.’ Scores were summed across the eight categories (Table 1), with a maximum score of 8; higher scores indicated better quality. Studies with low scores (<5) were excluded.

Statistical analysis

Outcome measures were analyzed using Cochrane Review Manager (RevMan version 5.3; Cochrane Collaboration, Oxford, UK). Studies were pooled using fixed-effect (I2 ≤50%) or random-effects models (I2 >50%). MDs were used for continuous outcomes (serum/plasma 25(OH)D concentrations), and ORs were used for the prevalence of VD deficiency and insufficiency. Subgroup analyses were conducted by age (infants and children 0–<6 years, adolescents 6–<18 years, adults 18–<60 years, and older participants ≥60 years); VD detection method, including chemiluminescence microparticle immunoassay (CMIA), chemiluminescence enzyme immunoassay (CLIA), electrochemiluminescence enzyme immunoassay (ECLIA), enzyme-linked immunosorbent assay (ELISA), liquid chromatography-tandem mass spectrometry/mass spectrometry (LC-MS/MS), and high-performance liquid chromatography (HPLC); criteria for VD deficiency (less than 10, 12, 15, and 20 ng/mL) and insufficiency (7–15, 10–20, 12–20, 15–20, 10–30, and 20–30 ng/mL); and obesity grade in participants without diagnosed MetS (mild obesity: 95%≤ BMI <97% or 30≤ BMI <35 or 2≤ BMIZ <3; moderate to severe obesity: BMI ≥97% or BMI ≥35 or BMIZ ≥3). Forest plots were generated to present MDs and ORs for all outcomes. A two-sided P<0.05 was considered statistically significant.

RESULTS

Characteristics of the included studies

The database searches identified 5,283 studies: 4,946 from PubMed, 65 from Embase, 29 from Web of Science, 16 from Wanfang Database, 206 from China Science and Technology Periodical Database, and 21 from the Cochrane Database of Systematic Reviews for systematic reviews and meta-analyses. After initial screening of titles and abstracts, 5,189 articles were excluded: 4,206 were irrelevant, 205 concerned MUO, 21 were systematic reviews and meta-analyses, 568 were animal experiments, 174 concerned obesity treatments, seven were in vitro experiments, and eight were duplicates. The remaining 94 studies were supplemented with 41 studies identified from the references of meta-analyses, yielding 135 studies for full-text assessment. Ultimately, 74 eligible studies were included after 61 studies were excluded (29 had incomplete information, 26 were in vitro experiments, and six did not meet the inclusion criteria). The included studies comprised 86,833 control participants and 24,005 obesity cases without diagnosed MetS. The study selection flowchart is shown in Fig. 1.

The characteristics of the 74 included studies are presented in Table 1.4-7,10-79 Complete data on serum/plasma 25(OH)D concentrations and the prevalence of VD deficiency and insufficiency were available in 54, 57, and 37 articles, respectively. By obesity grade, 69 and five studies were classified into the mild and moderate to severe obesity subgroups, respectively. Study populations included infants and children (n=32), adolescents (n=27), adults (n=13), and older participants (n=2). VD detection methods included CMIA (n=16), CLIA (n=17), ECLIA (n=8), ELISA (n=23), LC-MS/MS (n=6), and HPLC (n=4). The 57 articles reporting VD deficiency used different thresholds: <7 ng/mL (n=1), <10 ng/mL (n=6), <12 ng/mL (n=10), <15 ng/mL (n=6), and <20 ng/mL (n=34). Among the 37 studies reporting VD insufficiency, the thresholds were 7–15 (n=1), 10–20 (n=1), 12–20 (n=9), 15–20 (n=5), 10–30 (n=4), and 20–30 ng/mL (n=17).

Relationship between serum/plasma 25(OH)D concentrations and the risk of obesity without diagnosed MetS

As shown in Table 1 and Fig. 2, differences in serum/plasma 25(OH)D levels between the obesity (n=16,259) and control (n=69,610) groups were assessed in the 54 studies using a random-effects model with high heterogeneity (I2=100%).4-7,10-14,16,17,20-23,26-32,34-36,38-45,47-54,56,57,61,64-68,71,72,74-76 Individuals with obesity without diagnosed MetS had significantly lower serum/plasma 25(OH)D levels than in the control groups (MD=–3.98; 95% CI, –4.70 to –3.27; P<0.001). In subgroup analyses by age (Supplementary Fig. 1), VD detection methods (Supplementary Fig. 2), and obesity grades (Supplementary Fig. 3), serum/plasma 25(OH)D concentrations were significantly lower in the obesity groups than in the control groups among infants and children (MD=–3.47; 95% CI, –5.71 to –1.23; P=0.002) (Supplementary Fig. 1A), adolescents (MD=–3.90; 95% CI, –4.72 to –3.09; P<0.001) (Supplementary Fig. 1B), adults (MD=–4.34; 95% CI, –5.76 to –2.92; P<0.001) (Supplementary Fig. 1C) and older participants (MD=–3.23; 95% CI, –4.30 to –2.17; P<0.001) (Supplementary Fig. 1D). Moreover, 25(OH)D levels were lower in the obesity groups than in the control groups using CMIA/CLIA/ECLIA (MD=–3.88; 95% CI, –4.59 to –3.17; P<0.001) (Supplementary Fig. 2A) and ELISA (MD=–4.67; 95% CI, –6.36 to –2.97; P<0.001) (Supplementary Fig. 2B), whereas no significant difference was observed with LC-MS/MS and HPLC detection (MD=–1.16; 95% CI, –2.92 to 0.59; P=0.19) (Supplementary Fig. 2C). Furthermore, the pooled MD indicated significantly lower concentrations in both the mild (MD=–3.84; 95% CI, –4.58 to –3.11; P<0.001) (Supplementary Fig. 3A) and moderate to severe obesity subgroups than in their respective control groups (MD= –6.14; 95% CI, –11.11 to –1.18; P=0.02) (Supplementary Fig. 3B).

Figure 2.

Figure 2

Comparisons of serum/plasma 25-hydroxyvitamin D concentrations between the obesity and control groups. SD, standard deviation; IV, inverse-variance; CI, confidence interval.

Analysis of the prevalence of VD deficiency between obese and control groups

Fig. 3 presents the prevalence of VD deficiency in the obesity and control groups across 57 studies.4,5,10-16,18-21,23-27,29-35,37,38,41,43,45-50, 52,53,55,58-63,65,67-74,76-79 Compared with the control groups, the prevalence of VD deficiency was significantly higher in the obese groups using a random-effects model (I2=89%) (OR, 2.02; 95% CI, 1.73 to 2.36; P<0.001). Subgroup analyses were conducted by age (Supplementary Fig. 4), VD detection methods (Supplementary Fig. 5), obesity grades (Supplementary Fig. 6), and VD assessment criteria (Supplementary Fig. 7). In age-stratified analyses, the prevalence of VD deficiency was higher in the obesity groups than in the control groups among infants and children (OR, 2.33; 95% CI, 1.37 to 3.96; P=0.002) (Supplementary Fig. 4A), adolescents (OR, 2.07; 95% CI, 1.67 to 2.57; P<0.001) (Supplementary Fig. 4B), adults and older participants (OR, 1.80; 95% CI, 1.49 to 2.18; P<0.001) (Supplementary Fig. 4C). Moreover, using the subgroup analysis of VD detection methods, the prevalence of VD deficiency was higher in the obese groups than in the control groups using CMIA/CLIA/ECLIA (OR, 2.09; 95% CI, 1.72 to 2.54; P<0.001) (Supplementary Fig. 5A), ELISA (OR, 2.30; 95% CI, 1.55 to 3.41; P<0.001) (Supplementary Fig. 5B), and LC-MS/MS and HPLC methods (OR, 2.31; 95% CI, 1.47 to 3.62; P<0.001) (Supplementary Fig. 5C). Furthermore, in analyses by obesity grade, the prevalence of VD deficiency was higher in the obesity groups than in the control groups among both the mild (OR, 1.94; 95% CI, 1.68 to 2.26; P<0.001) (Supplementary Fig. 6A) and moderate to severe obesity subgroups without diagnosed MetS (OR, 4.78; 95% CI, 2.62 to 8.71; P<0.001) (Supplementary Fig. 6B). When different VD deficiency thresholds were considered, obese subjects had a significantly higher prevalence of VD deficiency than those in the control group in the subgroups using thresholds of less than 15 ng/mL (OR, 2.54; 95% CI, 1.98 to 3.26; P<0.001) (Supplementary Fig. 7C) and 20 ng/mL (OR, 2.26; 95% CI, 1.95 to 2.62; P<0.001) (Supplementary Fig. 7D). However, no significant difference was observed in the subgroups using thresholds of less than 10 ng/mL (OR, 1.17; 95% CI, 0.92 to 1.48; P=0.19) (Supplementary Fig. 7A) and 12 ng/mL (OR, 1.23; 95% CI, 0.98 to 1.55; P=0.08) (Supplementary Fig. 7B). Overall, differences in VD deficiency prevalence between the obesity and control groups were more pronounced when the threshold used to define VD deficiency was increased to more than 15 ng/mL.

Figure 3.

Figure 3

Comparisons of the prevalence of vitamin D deficiency between the obesity and control groups. M-H, Mantel-Haenszel; CI, confidence interval.

Prevalence of VD insufficiency between obese and control groups

Of the 74 studies, 37 reported the prevalence of VD insufficiency in both the obesity and control groups.4,10-13,16,18,20,23,24,26,27,29,30,32,37,38, 41,43,45,47-50,52,53,58,59,61,63,68-70,72,73,77,78 Compared with the control group, the pooled OR for VD insufficiency was higher in the obesity groups (OR, 1.17; 95% CI, 1.04 to 1.32; P=0.010) using a random-effects model (I2=81%) (Fig. 4). Subgroup analyses of VD insufficiency prevalence were conducted by age, VD detection method, VD assessment criteria, and obesity grade. In age-stratified analyses, the prevalence of VD insufficiency was significantly higher among adolescents with obesity than in the control groups (OR, 1.23; 95% CI, 1.07 to 1.42; P=0.005) (Supplementary Fig. 8B), whereas no significant differences were observed between the obesity and control groups among infants and children (OR, 1.00; 95% CI, 0.74 to 1.37; P=0.98) (Supplementary Fig. 8A), adults and older participants (OR, 1.14; 95% CI, 0.86 to 1.53; P=0.36) (Supplementary Fig. 8C). Moreover, in subgroup analyses by VD detection method, the prevalence of VD insufficiency was significantly higher among participants with obesity than in the control groups using both ELISA (OR, 1.46; 95% CI, 1.06 to 2.02; P=0.020) (Supplementary Fig. 9B) and LC-MS/MS and HPLC methods (OR, 1.10; 95% CI, 1.04 to 1.16; P<0.001) (Supplementary Fig. 9C), whereas no significant difference was observed with CMIA/CLIA/ECLIA (OR, 1.09; 95% CI, 0.92 to 1.29; P=0.32) (Supplementary Fig. 9A). In analyses by obesity grade, the prevalence of VD insufficiency was higher in the mild obesity groups than in controls (OR, 1.20; 95% CI, 1.06 to 1.35; P=0.004) (Supplementary Fig. 10A), whereas no significant difference was observed in the moderate to severe obesity groups (OR, 0.81; 95% CI, 0.59 to 1.11; P=0.19) (Supplementary Fig. 10B).

Figure 4.

Figure 4

Comparisons of the prevalence of vitamin D insufficiency between the obesity and control groups. M-H, Mantel-Haenszel; CI, confidence interval.

DISCUSSION

This meta-analysis, including 86,833 control participants and 24,005 individuals with obesity, showed that serum/plasma 25(OH)D concentrations were inversely associated with obesity without diagnosed MetS (MD=–3.98; 95% CI, –4.70 to –3.27). Moreover, VD deficiency was more prevalent in the obesity group than in the control group (OR, 2.02; 95% CI, 1.73 to 2.36). VD insufficiency was also positively associated with obesity (OR, 1.17; 95% CI, 1.04 to 1.32). Overall, these findings indicated an inverse association between VD status and obesity without diagnosed MetS.

Previous meta-analyses suggested that confounding factors, including age, VD detection methods, VD assessment criteria, and obesity grade, may bias relative risk estimates upwards and contribute to inconsistent results.3-6 Notably, previous studies have shown that serum/plasma VD status may be influenced by participant characteristics, which vary across age groups and obesity grades.7-9,61 In addition, VD requirements for fat accumulation and bone growth vary across age groups.57,79 The balance between serum/plasma 25(OH)D and VD stores is regulated by several important enzymes, including CYP27A1, CYP2R1, and CYP27B1.6,50 Previous studies have shown that these enzymes may also be regulated by age and obesity grade.6,70 Moreover, new insights into VD mechanisms of action suggest that serum/plasma VD status may be assessed using distinct non-canonical VD metabolites. However, optimal 25(OH)D levels remain debated, complicating interpretation of the available studies. Current VD detection methods include CMIA, CLIA, ECLIA, ELISA, LC-MS/MS, and HPLC, which differ in sensitivity and specificity.4 Although LC-MS/MS is considered a better method, results for VD levels and VD deficiency were inconsistent, with only six studies available.7,19,20,34,53,60 Thus, associations between obesity and VD deficiency prevalence assessed using LC-MS/MS require further investigation in additional studies. Furthermore, diagnostic criteria for VD deficiency and insufficiency vary slightly across countries.10-80 When considering only the relationship between VD and obesity risk, the need for VD insufficiency criteria is unclear. In summary, confounding factors, including age, VD detection methods, VD assessment criteria, and obesity grade, may contribute substantially to the high heterogeneity of outcomes in this meta-analysis (I2 >50%). This heterogeneity provided an important rationale for subgroup analyses. Our meta-analysis showed that serum/plasma 25(OH)D concentrations were negatively associated with obesity across all subgroups except those using LC-MS/MS and HPLC detection. Moreover, VD deficiency prevalence was significantly higher in the obesity groups across these subgroups, except those defining VD deficiency as a concentration below 10 or 12 ng/mL. Furthermore, VD insufficiency was positively associated with obesity in specific subgroups: adolescents, participants with mild obesity, and those assessed using ELISA, LC-MS/MS, or HPLC. These inconsistencies may be influenced by VD detection methods and assessment criteria. A possible explanation involves VD storage and metabolism and related dose-response effects: adipose tissue and adipocytes in individuals with obesity may sequester more VD, reducing its effective serum/plasma concentration. In addition, VD may affect cell proliferation and differentiation and thereby influence obesity development at higher 25(OH)D concentrations. Current diagnostic criteria primarily concern bone health rather than lipid metabolism.4-7 These results were consistent with most findings in the existing literature.4-12 Previous meta-analyses also supported our conclusion.59,80 In contrast, previous meta-analyses of prospective studies reported conflicting evidence regarding significant associations between obesity risk and VD deficiency in the overall population.3,4,52

Nevertheless, several limitations require consideration. First, although we comprehensively searched the electronic literature across multiple databases, some relevant studies may have been missed. Second, the included studies were observational and had limited inferential strength and high heterogeneity (I2 > 50%). Long-term effects should therefore be evaluated in larger, higherquality studies. Third, VD-related data on sun exposure and diet were lacking. Finally, obesity may cause metabolic changes that affect VD metabolism and potentially aggravate obesity progression. Thus, the present findings support significant associations between obesity and VD deficiency but cannot establish causality.

In conclusion, our meta-analysis suggested that VD status was inversely associated with the risk of obesity without diagnosed MetS, irrespective of age and obesity grade. Inconsistencies may be influenced by VD detection methods and assessment criteria. Our findings suggested that serum/plasma 25(OH)D concentrations were more appropriate for evaluating the relationship between VD status and obesity. In addition, thresholds below 15 or 20 ng/mL may be more appropriate for defining VD deficiency. These findings require validation in larger, higher-quality studies. Further mechanistic studies are also needed to identify the molecules and pathways underlying these interactions.

SUPPLEMENTARY MATERIALS

Supplementary materials can be found online at https://doi.org/10.7570/jomes25048.

ACKNOWLEDGMENTS

This study was supported by the National Natural Science Foundation of China (82173524 to Ping Li) and Funding for Reform and Development of Beijing Municipal Health Commission.

CONFLICTS OF INTEREST

The authors declare no conflict of interest.

AUTHOR CONTRIBUTIONS

Study concept and design: YL, XL, XJ, and PL; acquisition of data: YL, XL, and PL; analysis and interpretation of data: YL, XL, XJ, and TT; drafting of the manuscript: YL and PL; critical revision of the manuscript: KQ; statistical analysis: YL, XL, and TT; obtained funding: PL; administrative, technical, or material support: YL, XL, and XJ; and study supervision: KQ and PL.

References

  • 1.Gong HJ, Tang X, Zhou JB. The association between weight change patterns and obesity-related complex multimorbidity: evidence from NHANES. Front Endocrinol (Lausanne) 2024;15:1400204. 10.3389/fendo.2024.1400204 [DOI] [PMC free article] [PubMed]
  • 2.Tsatsoulis A, Paschou SA. Metabolically healthy obesity: criteria, epidemiology, controversies, and consequences. Curr Obes Rep 2020;9:109-20. 10.1007/s13679-020-00375-0 [DOI] [PubMed]
  • 3.Haghighat N, Sohrabi Z, Bagheri R, Akbarzadeh M, Esmaeilnezhad Z, Ashtary-Larky D, et al. A systematic review and meta-analysis of vitamin D status of patients with severe obesity in various regions worldwide. Obes Facts 2023;16:519-39. 10.1159/000533828 [DOI] [PMC free article] [PubMed]
  • 4.Li HA, Zou SQ, Li BT, Wang T, Ma ZC, Luo Q, et al. Serum vitamin D status among healthy children in Hainan, South China: a multi-center analysis of 10,262 children. Transl Pediatr 2022;11:1010-7. 10.21037/tp-22-235 [DOI] [PMC free article] [PubMed]
  • 5.Poomthavorn P, Saowan S, Mahachoklertwattana P, Chailurkit L, Khlairit P. Vitamin D status and glucose homeostasis in obese children and adolescents living in the tropics. Int J Obes (Lond) 2012;36:491-5. 10.1038/ijo.2011.260 [DOI] [PubMed]
  • 6.Aypak C, Türedi O, Yüce A. The association of vitamin D status with cardiometabolic risk factors, obesity and puberty in children. Eur J Pediatr 2014;173:367-73. 10.1007/s00431-013-2177-2 [DOI] [PubMed]
  • 7.Gariballa S, Shah I, Yasin J, Alessa A. Vitamin D [25(OH)D] metabolites and epimers in obese subject: interaction and correlations with adverse metabolic health risk factors. J Steroid Biochem Mol Biol 2022;215:106023. 10.1016/j.jsbmb.2021.106023 [DOI] [PubMed]
  • 8.Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and metaanalyses: the PRISMA statement. Ann Intern Med 2009;151:264-9, W64. 10.7326/0003-4819-151-4-200908180-00135 [DOI] [PubMed]
  • 9.Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Ottawa Hospital Research Institute; 2022 [cited 2026 Oct 11]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
  • 10.Çelik N, Doğan HO, Zararsiz G. Different threshold levels of circulating total and free 25-hydroxyvitamin D for the diagnosis of vitamin D deficiency in obese adolescents. Eur J Pediatr 2021;180:2619-27. 10.1007/s00431-021-04137-5 [DOI] [PubMed]
  • 11.Barja-Fernández S, Aguilera CM, Martínez-Silva I, Vazquez R, Gil-Campos M, Olza J, et al. 25-Hydroxyvitamin D levels of children are inversely related to adiposity assessed by body mass index. J Physiol Biochem 2018;74:111-8. 10.1007/s13105-017-0581-1 [DOI] [PubMed]
  • 12.Gün E, Uzun H, Bolu S, Arslanoğlu İ, Kocabay K. Serum 25-hydroxyvitamin D is associated with insulin resistance independently of obesity in children ages 5-17. Prim Care Diabetes 2020;14:741-6. 10.1016/j.pcd.2020.06.006 [DOI] [PubMed]
  • 13.Bellone S, Esposito S, Giglione E, Genoni G, Fiorito C, Petri A, et al. Vitamin D levels in a paediatric population of normal weight and obese subjects. J Endocrinol Invest 2014;37:805-9. 10.1007/s40618-014-0108-3 [DOI] [PubMed]
  • 14.Colak R, Anil M, Yasar F, Rahmi Bakiler A, Pirgon O, Helvaci M, et al. Metabolic disturbances and cardiovascular risk factors in obese children with vitamin D deficiency. Arch Pediatr 2020;27:140-5. 10.1016/j.arcped.2019.12.005 [DOI] [PubMed]
  • 15.Flores A, Flores M, Macias N, Hernández-Barrera L, Rivera M, Contreras A, et al. Vitamin D deficiency is common and is associated with overweight in Mexican children aged 1-11 years. Public Health Nutr 2017;20:1807-15. 10.1017/S1368980017000040 [DOI] [PMC free article] [PubMed]
  • 16.Huang K, Jiang YJ, Fu JF, Liang JF, Zhu H, Zhu ZW, et al. The relationship between serum 25-hydroxyvitamin D and glucose homeostasis in obese children and adolescents in Zhejiang, China. Endocr Pract 2015;21:1117-24. 10.4158/EP15694.OR [DOI] [PubMed]
  • 17.Saarnio E, Pekkinen M, Itkonen ST, Kemi V, Karp H, Ivaska KK, et al. Low free 25-hydroxyvitamin D and high vitamin D binding protein and parathyroid hormone in obese Caucasians: a complex association with bone? PLoS One 2018;13:e0192596. 10.1371/journal.pone.0192596 [DOI] [PMC free article] [PubMed]
  • 18.Moschonis G, Androutsos O, Hulshof T, Dracopoulou M, Chrousos GP, Manios Y. Vitamin D insufficiency is associated with insulin resistance independently of obesity in primary schoolchildren: the healthy growth study. Pediatr Diabetes 2018;19:866-73. 10.1111/pedi.12678 [DOI] [PubMed]
  • 19.Wakayo T, Whiting SJ, Belachew T. Vitamin D deficiency is associated with overweight and/or obesity among schoolchildren in central Ethiopia: a cross-sectional study. Nutrients 2016;8:190. 10.3390/nu8040190 [DOI] [PMC free article] [PubMed]
  • 20.Chen Z, Lv X, Hu W, Qian X, Wu T, Zhu Y. Vitamin D status and its influence on the health of preschool children in Hangzhou. Front Public Health 2021;9:675403. 10.3389/fpubh.2021.675403 [DOI] [PMC free article] [PubMed]
  • 21.Zhao Y, Qin R, Hong H, Lv H, Ye K, Wei Y, et al. Is vitamin D deficiency influenced by obesity during the first 5 years of life? A cross-sectional multicenter study. Food Sci Nutr 2023;11:1084-95. 10.1002/fsn3.3145 [DOI] [PMC free article] [PubMed]
  • 22.Gilbert-Diamond D, Baylin A, Mora-Plazas M, Marin C, Arsenault JE, Hughes MD, et al. Vitamin D deficiency and anthropometric indicators of adiposity in school-age children: a prospective study. Am J Clin Nutr 2010;92:1446-51. 10.3945/ajcn.2010.29746 [DOI] [PMC free article] [PubMed]
  • 23.Guo B, Zhang Y, Lu J, Guo S, Jiang Y, Pei J, et al. Association between serum 25-hydroxyvitamin D concentrations and obesity in one-year-old Chinese infants. Food Sci Nutr 2021;9:3191-9. 10.1002/fsn3.2279 [DOI] [PMC free article] [PubMed]
  • 24.Jari M, Qorbani M, Moafi M, Motlagh ME, Keikha M, Ardalan G, et al. Association of 25-hydroxy vitamin D levels with indexes of general and abdominal obesity in Iranian adolescents: the CASPIAN-III study. J Res Med Sci 2015;20:122-6. [PMC free article] [PubMed]
  • 25.Khor GL, Chee WSS, Shariff ZM, Poh BK, Arumugam M, Rahman JA, et al. High prevalence of vitamin D insufficiency and its association with BMI-for-age among primary school children in Kuala Lumpur, Malaysia. BMC Public Health 2011;11:95. 10.1186/1471-2458-11-95 [DOI] [PMC free article] [PubMed]
  • 26.Krivošíková K, Krivošíková Z, Wsolová L, Seeman T, Podracká Ľ. Hypertension in obese children is associated with vitamin D deficiency and serotonin dysregulation. BMC Pediatr 2022;22:289. 10.1186/s12887-022-03337-8 [DOI] [PMC free article] [PubMed]
  • 27.Zou Y, Zhang R, Huang L, Zhao D, Su D, Meng J, et al. Serum levels of vitamin D, retinol, zinc, and CRP in relation to obesity among children and adolescents. Eur J Med Res 2022;27:51. 10.1186/s40001-022-00670-7 [DOI] [PMC free article] [PubMed]
  • 28.Usman M, Woloshynowych M, Britto JC, Bilkevic I, Glassar B, Chapman S, et al. Obesity, oxidative DNA damage and vitamin D as predictors of genomic instability in children and adolescents. Int J Obes (Lond) 2021;45:2095-107. 10.1038/s41366-021-00879-2 [DOI] [PMC free article] [PubMed]
  • 29.Al-Sultan AI, Amin TT, Abou-Seif MA, Al Naboli MR. Vitamin D, parathyroid hormone levels and insulin sensitivity among obese young adult Saudis. Eur Rev Med Pharmacol Sci 2011;15:135-47. [PubMed]
  • 30.Olson ML, Maalouf NM, Oden JD, White PC, Hutchison MR. Vitamin D deficiency in obese children and its relationship to glucose homeostasis. J Clin Endocrinol Metab 2012;97:279-85. 10.1210/jc.2011-1507 [DOI] [PMC free article] [PubMed]
  • 31.Ghergherechi R, Hazhir N, Tabrizi A. Comparison of vitamin D deficiency and secondary hyperparathyroidism in obese and non-obese children and adolescents. Pak J Biol Sci 2012;15:147-51. 10.3923/pjbs.2012.147.151 [DOI] [PubMed]
  • 32.Dyląg H, Rowicka G, Strucińska M, Riahi A. Assessment of vitamin D status in children aged 1-5 with simple obesity. Rocz Panstw Zakl Hig 2014;65:325-30. [PubMed]
  • 33.Senaprom S, Yamborisut U, Rojroongwasinkul N, Wimonpeerapattana W, Purttiponthanee S, Khouw I, et al. Factors associated with vitamin D status among Thai children aged 3-13 years. Southeast Asian J Trop Med Public Health 2016;47:277-86. [PubMed]
  • 34.Orces CH. The association between obesity and vitamin D status among older adults in Ecuador: analysis of the SABE survey. Nutr Hosp 2018;35:1066-71. 10.20960/nh.1752 [DOI] [PubMed]
  • 35.Aka S, Kilercik M, Arapoglu M, Semiz S. The hepcidin and 25-OH-vitamin D levels in obese children as a potential mediator of the iron status. Clin Lab 2021;67:1154-62. 10.7754/Clin.Lab.2020.200813 [DOI] [PubMed]
  • 36.Al-Musharaf S, Al-Othman A, Al-Daghri NM, Krishnaswamy S, Yusuf DS, Alkharfy KM, et al. Vitamin D deficiency and calcium intake in reference to increased body mass index in children and adolescents. Eur J Pediatr 2012;171:1081-6. 10.1007/s00431-012-1686-8 [DOI] [PubMed]
  • 37.Durá-Travé T, Gallinas-Victoriano F, Malumbres-Chacon M, Ahmed-Mohamed L, Chueca-Guindulain MJ, Berrade-Zubiri S. Are there any seasonal variations in 25-hydroxyvitamin D and parathyroid hormone serum levels in children and adolescents with severe obesity? Eur J Pediatr 2021;180:1203-10. 10.1007/s00431-020-03857-4 [DOI] [PubMed]
  • 38.Durá-Travé T, Gallinas-Victoriano F, Chueca-Guindulain MJ, Berrade-Zubiri S, Urretavizcaya-Martinez M, Ahmed-Mohamed L. Assessment of vitamin D status and parathyroid hormone during a combined intervention for the treatment of childhood obesity. Nutr Diabetes 2019;9:18. 10.1038/s41387-019-0083-z [DOI] [PMC free article] [PubMed]
  • 39.Jaksic M, Martinovic M, Gligorovic-Barhanovic N, Vujacic A, Djurovic D, Nedovic-Vukovic M. Association between inflammation, oxidative stress, vitamin D, copper and zinc with pre-obesity and obesity in school children from the city of Podgorica, Montenegro. J Pediatr Endocrinol Metab 2019;32:951-7. 10.1515/jpem-2019-0086 [DOI] [PubMed]
  • 40.Shulhai AM, Pavlyshyn H, Shulhai O. Relation of carbohydrate exchange markers with vitamin D status in adolescents with overweight and obesity. Pediatr Endocrinol Diabetes Metab 2019;25:169-76. 10.5114/pedm.2019.89640 [DOI] [PubMed]
  • 41.Elizondo-Montemayor L, Ugalde-Casas PA, Serrano-González M, Cuello-García CA, Borbolla-Escoboza JR. Serum 25-hydroxyvitamin D concentration, life factors and obesity in Mexican children. Obesity (Silver Spring) 2010;18:1805-11. 10.1038/oby.2009.448 [DOI] [PubMed]
  • 42.Peterson CA, Tosh AK, Belenchia AM. Vitamin D insufficiency and insulin resistance in obese adolescents. Ther Adv Endocrinol Metab 2014;5:166-89. 10.1177/2042018814547205 [DOI] [PMC free article] [PubMed]
  • 43.Simunovic M, Supe-Domic D, Karin Z, Degoricija M, Paradzik M, Skrabic R, et al. The relationship of vitamin D status, adherence to the Mediterranean diet, and physical activity in obese children and adolescents. J Med Food 2021;24:385-93. 10.1089/jmf.2020.0032 [DOI] [PubMed]
  • 44.Reinehr T, de Sousa G, Alexy U, Kersting M, Andler W. Vitamin D status and parathyroid hormone in obese children before and after weight loss. Eur J Endocrinol 2007;157:225-32. 10.1530/EJE-07-0188 [DOI] [PubMed]
  • 45.Rojas LZ, Quintero-Lesmes DC, Gamboa-Delgado EM, Guio E, Serrano NC. Prevalence of vitamin D status and its association with overweight or obesity in a population of Colombian children and adolescents. J Nutr Sci 2020;9:e55. 10.1017/jns.2020.47 [DOI] [PMC free article] [PubMed]
  • 46.Zhang HQ, Teng JH, Li Y, Li XX, He YH, He X, et al. Vitamin D status and its association with adiposity and oxidative stress in schoolchildren. Nutrition 2014;30:1040-4. 10.1016/j.nut.2014.02.024 [DOI] [PubMed]
  • 47.Liu RP, Chen Y, Wu HB, Xiong FM, He FY, Li YY. Levels of fat-soluble vitamins A, D, and E and their influencing factors in children with obesity. Zhongguo Dang Dai Er Ke Za Zhi 2022;24:572-8. [DOI] [PMC free article] [PubMed]
  • 48.Xie H, Min M, Guo S, Xian Y, Yang F, Wang X, et al. Impact of vitamin D and vitamin D receptor on risk of cardiovascular diseases in children and adolescents with obesity in Sichuan, China: a cross-sectional study. Ann Nutr Metab 2020;76:396-404. 10.1159/000513287 [DOI] [PubMed]
  • 49.Wang L, Wang H, Wen H, Tao H, Zhao X. Relationship between HOMA-IR and serum vitamin D in Chinese children and adolescents. J Pediatr Endocrinol Metab 2016;29:777-81. 10.1515/jpem-2015-0422 [DOI] [PubMed]
  • 50.Vierucci F, Del Pistoia M, Fanos M, Gori M, Carlone G, Erba P, et al. Vitamin D status and predictors of hypovitaminosis D in Italian children and adolescents: a cross-sectional study. Eur J Pediatr 2013;172:1607-17. 10.1007/s00431-013-2119-z [DOI] [PubMed]
  • 51.Makariou SE, Challa A, Siomou E, Tellis C, Tselepis A, Elisaf M, et al. Vitamin D status and cardiometabolic risk factors in Greek adolescents with obesity: the effect of vitamin D supplementation: a pilot study. Arch Med Sci Atheroscler Dis 2020;5:e64-71. 10.5114/amsad.2020.95569 [DOI] [PMC free article] [PubMed]
  • 52.Plesner JL, Dahl M, Fonvig CE, Nielsen TRH, Kloppenborg JT, Pedersen O, et al. Obesity is associated with vitamin D deficiency in Danish children and adolescents. J Pediatr Endocrinol Metab 2018;31:53-61. 10.1515/jpem-2017-0246 [DOI] [PubMed]
  • 53.Hu Y, Jiang S, Lu J, Yang Z, Yang X, Yang L. Vitamin D status for Chinese children and adolescents in CNNHS 2016-2017. Nutrients 2022;14:4928. 10.3390/nu14224928 [DOI] [PMC free article] [PubMed]
  • 54.Nikooyeh B, Hollis BW, Neyestani TR. Modulating effect of vitamin D status on serum anti-adenovirus 36 antibody amount in children with obesity: National Food and Nutrition Surveillance. BMC Pediatr 2020;20:316. 10.1186/s12887-020-02216-4 [DOI] [PMC free article] [PubMed]
  • 55.Sacheck J, Goodman E, Chui K, Chomitz V, Must A, Economos C. Vitamin D deficiency, adiposity, and cardiometabolic risk in urban schoolchildren. J Pediatr 2011;159:945-50. 10.1016/j.jpeds.2011.06.001 [DOI] [PMC free article] [PubMed]
  • 56.Liu X, Xian Y, Min M, Dai Q, Jiang Y, Fang D. Association of 25-hydroxyvitamin D status with obesity as well as blood glucose and lipid concentrations in children and adolescents in China. Clin Chim Acta 2016;455:64-7. 10.1016/j.cca.2016.01.023 [DOI] [PubMed]
  • 57.Kitsos A, Dounousi E, Kalaitzidis R, Challa A, Siamopoulos KC, Tigas S. Serum vitamin D in obese and overweight subjects according to estimated glomerular filtration rate. Hormones (Athens) 2018;17:237-46. 10.1007/s42000-018-0022-8 [DOI] [PubMed]
  • 58.Al-Sadat N, Majid HA, Sim PY, Su TT, Dahlui M, Abu Bakar MF, et al. Vitamin D deficiency in Malaysian adolescents aged 13 years: findings from the Malaysian Health and Adolescents Longitudinal Research Team study (MyHeARTs). BMJ Open 2016;6:e010689. 10.1136/bmjopen-2015-010689 [DOI] [PMC free article] [PubMed]
  • 59.Panfili FM, Convertino A, Grugni G, Mazzitelli L, Bocchini S, Crinò A, et al. Multicentric Italian case-control study on 25OH vitamin D levels in children and adolescents with Prader-Willi syndrome. J Endocrinol Invest 2023;46:1397-406. 10.1007/s40618-022-01990-5 [DOI] [PubMed]
  • 60.Clark P, Montiel-Ojeda D, Chico-Barba LG, López-González D, Méndez-Sánchez L, Guagnelli-Martínez MA. Vitamin D concentration and its association with parathyroid hormone in children and adolescents. Bol Med Hosp Infant Mex 2021;78:265-72. 10.24875/BMHIM.20000243 [DOI] [PubMed]
  • 61.Durá-Travé T, Gallinas-Victoriano F, Chueca-Guindulain MJ, Berrade-Zubiri S. Prevalence of hypovitaminosis D and associated factors in obese Spanish children. Nutr Diabetes 2017;7:e248. 10.1038/nutd.2016.50 [DOI] [PMC free article] [PubMed]
  • 62.Turer CB, Lin H, Flores G. Prevalence of vitamin D deficiency among overweight and obese US children. Pediatrics 2013;131:e152-61. 10.1542/peds.2012-1711 [DOI] [PubMed]
  • 63.Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006;29:2244-6. 10.2337/dc06-0946 [DOI] [PubMed]
  • 64.Lee SH, Kim SM, Park HS, Choi KM, Cho GJ, Ko BJ, et al. Serum 25-hydroxyvitamin D levels, obesity and the metabolic syndrome among Korean children. Nutr Metab Cardiovasc Dis 2013;23:785-91. 10.1016/j.numecd.2012.04.013 [DOI] [PubMed]
  • 65.Absoud M, Cummins C, Lim MJ, Wassmer E, Shaw N. Prevalence and predictors of vitamin D insufficiency in children: a Great Britain population based study. PLoS One 2011;6:e22179. 10.1371/journal.pone.0022179 [DOI] [PMC free article] [PubMed]
  • 66.Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr 2002;76:187-92. 10.1093/ajcn/76.1.187 [DOI] [PubMed]
  • 67.Holvik K, Meyer HE, Haug E, Brunvand L. Prevalence and predictors of vitamin D deficiency in five immigrant groups living in Oslo, Norway: the Oslo Immigrant Health Study. Eur J Clin Nutr 2005;59:57-63. 10.1038/sj.ejcn.1602033 [DOI] [PubMed]
  • 68.Rockell JE, Green TJ, Skeaff CM, Whiting SJ, Taylor RW, Williams SM, et al. Season and ethnicity are determinants of serum 25-hydroxyvitamin D concentrations in New Zealand children aged 5-14 y. J Nutr 2005;135:2602-8. 10.1093/jn/135.11.2602 [DOI] [PubMed]
  • 69.Bischof MG, Heinze G, Vierhapper H. Vitamin D status and its relation to age and body mass index. Horm Res 2006;66:211-5. 10.1159/000094932 [DOI] [PubMed]
  • 70.Çizmecioğlu FM, Etiler N, Görmüş U, Hamzaoğlu O, Hatun Ş. Hypovitaminosis D in obese and overweight schoolchildren. J Clin Res Pediatr Endocrinol 2008;1:89-96. 10.4008/jcrpe.v1i2.43 [DOI] [PMC free article] [PubMed]
  • 71.Tseng M, Giri V, Bruner DW, Giovannucci E. Prevalence and correlates of vitamin D status in African American men. BMC Public Health 2009;9:191. 10.1186/1471-2458-9-191 [DOI] [PMC free article] [PubMed]
  • 72.Hyppönen E, Berry D, Cortina-Borja M, Power C. 25-Hydroxyvitamin D and pre-clinical alterations in inflammatory and hemostatic markers: a cross sectional analysis in the 1958 British Birth Cohort. PLoS One 2010;5:e10801. 10.1371/journal.pone.0010801 [DOI] [PMC free article] [PubMed]
  • 73.González L, Ramos-Trautmann G, Díaz-Luquis GM, Pérez CM, Palacios C. Vitamin D status is inversely associated with obesity in a clinic-based sample in Puerto Rico. Nutr Res 2015;35:287-93. 10.1016/j.nutres.2015.02.001 [DOI] [PMC free article] [PubMed]
  • 74.Stokić E, Kupusinac A, Tomić-Naglić D, Zavišić BK, Mitrović M, Smiljenić D, et al. Obesity and vitamin D deficiency: trends to promote a more proatherogenic cardiometabolic risk profile. Angiology 2015;66:237-43. 10.1177/0003319714528569 [DOI] [PubMed]
  • 75.Reyman M, Verrijn Stuart AA, van Summeren M, Rakhshandehroo M, Nuboer R, de Boer FK, et al. Vitamin D deficiency in childhood obesity is associated with high levels of circulating inflammatory mediators, and low insulin sensitivity. Int J Obes (Lond) 2014;38:46-52. 10.1038/ijo.2013.75 [DOI] [PubMed]
  • 76.Zhang HY, Zhang L, Ma CC, Wen ZF, Wei W, Jia LH. Survey on the serum vitamin D and its affecting factors in overweight and obese children aged 3-6 years from a kindergarten of Shenyang. Pract Prev Med 2014;21:1291-3.
  • 77.Xiao YL, Du P, Tan MZ, Zhang CL, Lin L, He JN, et al. Detection of serum vitamin D level in children with simple obesity and observation of intervention effect. J Guangdong Med Coll 2012;30:270-1.
  • 78.Alkerwi A, Sauvageot N, Gilson G, Stranges S. Prevalence and correlates of vitamin D deficiency and insufficiency in Luxembourg adults: evidence from the Observation of Cardiovascular Risk Factors (ORISCAV-LUX) Study. Nutrients 2015;7:6780-96. 10.3390/nu7085308 [DOI] [PMC free article] [PubMed]
  • 79.Miñambres I, Sánchez-Hernández J, Sánchez-Quesada JL, Rodríguez J, de Leiva A, Pérez A. The association of hypovitaminosis D with the metabolic syndrome is independent of the degree of obesity. ISRN Endocrinol 2012;2012:691803. 10.5402/2012/691803 [DOI] [PMC free article] [PubMed]
  • 80.Corsello A, Macchi M, D'Oria V, Pigazzi C, Alberti I, Treglia G, et al. Effects of vitamin D supplementation in obese and overweight children and adolescents: a systematic review and meta-analysis. Pharmacol Res 2023;192:106793. 10.1016/j.phrs.2023.106793 [DOI] [PubMed]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Journal of Obesity & Metabolic Syndrome are provided here courtesy of Korean Society for the Study of Obesity

RESOURCES